Literature DB >> 8751471

The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives.

M Schlesinger1, I Broman, G Lugassy.   

Abstract

The present study was aimed at analyzing the existence of an impaired complement system in CLL patients. For this purpose, the serum levels of the serum complement proteins C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, C9, Factor B and properdin were repeatedly evaluated by means of radial immunodiffusion assay in 26 CLL patients over a period of 2 years. At the time of diagnosis, 18 of the 26 CLL patients showed low serum levels in at least one of these complement proteins as compared to a group of sex- and age-matched healthy subjects (P < 0.0001). Complement defects affected either the classical and/or the alternative pathway components, and in some case low levels of late components (C5-C9) were also observed. A reduced level of properdin was the most frequent abnormality (11/18). The presence of such abnormalities were correlated with the stage of the disease, and they were found in 100% of the patients (11) in advanced stages (Rai II-IV), and in 40% of patients (15) in early stages (0-1) (P < 0.004). Severe infections occurred in five patients; four of them were in advanced stages of the disease and had decreased levels of at least one complement component, whereas the remaining patient was in an early stage and had normal levels of complement components. These data support the notion that an impaired complement system might be involved in the pathophysiology of CLL and its infectious complications. Although more work is needed to sustain this hypothesis, we discuss the possibility on the basis of data obtained in the first-degree relatives of CLL patients, that in some CLL patients the complement deficit might reflect a genetic predisposition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8751471

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  24 in total

Review 1.  A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Authors:  Mazie Tsang; Sameer A Parikh
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

2.  Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Authors:  Sameer A Parikh; Jose F Leis; Kari G Chaffee; Timothy G Call; Curtis A Hanson; Wei Ding; Asher A Chanan-Khan; Deborah Bowen; Michael Conte; Susan Schwager; Susan L Slager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Cancer       Date:  2015-04-30       Impact factor: 6.860

3.  Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach.

Authors:  Masami Kadowaki; Takafumi Sangai; Takeshi Nagashima; Masahiro Sakakibara; Hideyuki Yoshitomi; Shigetsugu Takano; Kazuyuki Sogawa; Hiroshi Umemura; Koya Fushimi; Yukio Nakatani; Fumio Nomura; Masaru Miyazaki
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-21       Impact factor: 4.553

Review 4.  Treatment of older patients with chronic lymphocytic leukemia.

Authors:  Nicole Lamanna
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

5.  Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia.

Authors:  Vesa Lindström; Janne Aittoniemi; Urpu Salmenniemi; Helena Käyhty; Heini Huhtala; Marjatta Sinisalo
Journal:  Hum Vaccin Immunother       Date:  2019-07-09       Impact factor: 3.452

Review 6.  Chronic lymphocytic leukemia and autoimmunity: a systematic review.

Authors:  Kate Hodgson; Gerardo Ferrer; Emili Montserrat; Carol Moreno
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

Review 7.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 8.  Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Authors:  Ricardo García-Muñoz; Luis Llorente
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

Review 9.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

10.  Proteotyping of knockout mouse strains reveals sex- and strain-specific signatures in blood plasma.

Authors:  Yassene Mohammed; Sarah A Michaud; Helena Pětrošová; Juncong Yang; Milan Ganguly; David Schibli; Ann M Flenniken; Lauryl M J Nutter; Hibret A Adissu; K C Kent Lloyd; Colin McKerlie; Christoph H Borchers
Journal:  NPJ Syst Biol Appl       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.